Soclenicant
Chemical compound
From Wikipedia, the free encyclopedia
Soclenicant (INN),[3] also known by its developmental code names BNC210 and IW-2143, is an antinicotinic agent which is under development for the treatment of anxiety disorders such as social phobia and generalized anxiety disorder, as well as for treatment of agitation, post-traumatic stress disorder (PTSD), and depressive disorders.[1][4][5] It is taken by mouth.[4]
- None
| |
| Clinical data | |
|---|---|
| Other names | BNC210; BNC-210; IW2143; IW-2143 |
| Routes of administration | Oral |
| Drug class | α7-Nicotinic acetylcholine receptor negative allosteric modulator |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 69.4% (rat)[1][2] |
| Protein binding | 70–88%[1][2] |
| Elimination half-life | 6.2 hours (rat)[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H26N4O3 |
| Molar mass | 418.497 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug acts as a highly selective negative allosteric modulator (NAM) of the α7-nicotinic acetylcholine receptor (α7-nAChR).[1][6][4][5] It produces anxiolytic-, anti-stress-, and antidepressant-like effects without causing sedation, memory or motor impairment, or physical dependence in rodents.[6] Chemically, soclenicant is a synthetic heterocyclic small-molecule compound based on a 1,8-naphthyridin-4-one scaffold, bearing amide and amine functionalities.[7]
Soclenicant is being developed by Bionomics.[4] It has also been developed by Ironwood Pharmaceuticals and EmpathBio.[4][5] Bionomics was acquired by Neuphoria Therapeutics in December 2024.[4] As of December 2024, soclenicant is in phase 3 clinical trials for anxiety disorders, phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders.[4][5] The drug received Fast Track designation from the United States Food and Drug Administration (FDA) in 2019.[8] It was first described in the literature, in a conference abstract, by 2007.[2]